Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Retinal Dystrophies: early-phase trial registry
6 of 11 indexed Retinal Dystrophies trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 6 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Retinal Dystrophies: 11 US clinical trials tracked, 6 recruiting.
Retinal Dystrophies is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is PYC Therapeutics, running 3 of these trials.
Enrollment posture brief
Registry condition retinal-dystrophies
OPEN 6 | RECR 55% | LATE 0 | EARLY 5 | RANK #1577 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)
Retinal Dystrophies lists 6 open slots (55% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Retinal Dystrophies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Retinal Dystrophies is recruiting above its size-band peers.
6 of 11 indexed trials (54.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Retinal Dystrophies research.
PYC Therapeutics accounts for 3 of 11 trials (27.3%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Retinal Dystrophies trials plan to enrol fewer than 100 people.
Median target enrolment is 22 among the 11 trials that report a genuine target (sentinel values excluded). 9 of those (81.8%) plan for fewer than 100 participants.
-
Retinal Dystrophies splits between interventional and observational designs.
7 interventional and 4 observational studies make up this index (63.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
EyeConic: Qualification for Cone-Optogenetics
Institute of Molecular and Clinical Ophthalmology Basel
NCT05294978
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
Ray Therapeutics
NCT06375239
SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)
Duke University
NCT06177977
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
PYC Therapeutics
NCT06852963
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
University of Rochester
NCT06319872
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
PYC Therapeutics
NCT06455826
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
PYC Therapeutics
NCT05573984
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Nanoscope Therapeutics
NCT06162585
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
ProQR Therapeutics
NCT04123626
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
Nanoscope Therapeutics
NCT04945772
Optical Head-Mounted Display Technology for Low Vision Rehabilitation
University of Michigan
NCT02983305
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Retinal Dystrophies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Retinal Dystrophies trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Retinal Dystrophies page
11 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Retinal Dystrophies trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- PYC Therapeutics sponsors the most Retinal Dystrophies trials on record, review their full trial history before evaluating a specific study. See PYC Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Retinal Dystrophies condition card totals 11 registered trials; most-linked intervention VP-001; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.